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Background. Transcatheter arterial lipiodol chemoembolization (TACE) can be used in cirrhotic patients with hepatocellular
carcinoma to avoid tumor progression before transplantation. Objective. To evaluate the eﬃcacy and safety of TACE used as a
bridgetolivertransplantation.Methods.TACEwasperformedin30cirrhoticpatientswithhepatocellularcarcinoma.Milancriteria
were used to select patients for transplant. Patients had a good or moderately impaired liver function, no arterioportal ﬁstulae,
and a good portal perfusion. Results. 48 TACE were performed in 30 patients. Before transplantation, 4 patients were dropped oﬀ
the list due to tumor extension or liver failure. Complete necrosis of the tumor was observed in 11 patients and partial necrosis in
15 patients. After transplantation, 6 patients died and tumor recurrence was observed in 5 patients with a tumor beyond Milan
criteria or no response to TACE. Conclusion. TACE is useful as a bridge to liver transplantation in a selected group of cirrhotic
patients with hepatocellular carcinoma. A combined therapeutic approach before surgery might improve the prognosis in these
patients.
1.Introduction
Incidence of hepatocellular carcinoma (HCC) has increased
signiﬁcantly over the last decades. Worldwide it represents
the ﬁfth most common cancer and the third cause of cancer
mortality among the general population [1, 2]. Hepatitis B
and C and alcohol abuse are major risk factors for HCC.
Several treatment modalities exist based on tumor location
and size. Among others, liver transplantation was conﬁrmed
as a valuable treatment for HCC during the 1990s as it
was observed that small incidental HCC discovered in the
explanted liver had no adverse impact on posttransplanta-
tion outcome [3, 4]. Thus, over the years, orthotopic liver
transplantation(OLT)hasbecomethemainstayoftreatment
for small centrally located HCC in a cirrhotic liver. Since
the late nineties, most transplantation centers have agreed
to perform liver transplantation for HCC based on Milan
criteria. The Milan criteria were elaborated by Figueras et
al. who showed that patients with one hepatic lesion smaller
than 5cm or with three lesions smaller than 3cm can expect
a 5-year survival rate after liver transplantation of 70% with
recurrence rate below 15% [5]. Those results were supported
b ys e v e r a lo t h e rr e s e a r c hg r o u p s[ 6–8].
However, the time waiting for an organ represents a
major pitfall to liver transplantation. This may lead to tumor
progression and subsequent ineligibility for transplantation.2 International Journal of Hepatology
In Europe and USA, there are reports that liver transplant
waiting lists are getting longer so that a growing number
of patients must be removed from the lists due to tumor
progression exceeding the accepted transplant criteria [2].
Dropout rates of more than 20% have recently been reported
[9].
Transcatheter arterial chemoembolization (TACE) has
been proposed as a treatment to bridge the waiting time
between the diagnosis and liver transplantation. In some
studies, it has been demonstrated that TACE may limit
tumor growth, diminish dropout rate, and cause signiﬁcant
tumor necrosis, which may reduce tumor dissemination
duringsurgeryandpossiblyrecurrences[10].However,some
studies have also showed opposite results [5, 11, 12].
The aim of this study was to evaluate retrospectively the
usefulness and tolerance of TACE before OLT in cirrhotic
patients with hepatocellular carcinoma.
2. Methods
From January 1st 1996 to January 1st 2008, all cirrhotic
patients with HCC listed for OLT and treated with TACE at
our transplantation center were included for analysis.
Diagnosis of HCC was made in accordance with the
European Association for the Study of the Liver (EASL)
guidelines: typical lesions on 2 imaging studies (computed
tomographic(CT)scan,magneticresonanceimaging(MRI),
ultrasound) or on 1 imaging modality with an elevated
serum alfa-fetoprotein over 400ng/ml or liver biopsy with
histologic conﬁrmation of HCC [13].
The selection of patients with HCC for TACE was based
on the following inclusion criteria: good or moderately
impaired hepatic function (Child Pugh classes A and B),
hepatopetal portal blood ﬂow, absence of portal vein throm-
bosis, absence of arterioportal ﬁstula, absence of exten-
sive portosystemic shunting, and a waiting time for liver
transplantation estimated to be more than 3 months. TACE
aimed both at limiting tumor progression and downstaging.
Downstaging was conducted in a limited number of patients
exceeding the Milan criteria. In those patients, TACE treat-
ments were administered until Milan criteria were reached
in order to become eligible for OLT.
All the patients signed an informed consent form and
the procedures were done in accordance with the Helsinki
declaration of 1975.
Selective TACE were performed by interventional angio-
radiologists (PP and LB) using cisplatin and lipiodol. Gel
Foam (Pﬁzer, Canada) was added to stasis following the
injection of the cisplatin-lipiodol solution into the hepatic
artery. Tumor response was assessed by CT scan and/or
MRI every 3 months post chemoembolization. Changes
in the tumor size of at least 5mm in diameter were
considered to be signiﬁcant. TACE was performed every 3
months according to response or until transplantation if
patients were eligible. Child Pugh scores and complications
were monitored following every treatment.
All patients transplanted received a cadaveric liver.
Explanted livers underwent extensive histologic analysis and
staging of HCC. The modiﬁed Edmondson scoring system
was used to grade the level of diﬀerentiation of HCC nodules
[14].
All patients were followed until death or January 2009.
In the follow-up period, surgical complications, hepatitis
recurrence, HCC recurrence, and patients survival were ana-
lysed.
Categorical data were compared using the Fischer exact
test. Hazard ratio associated with the Milan criteria and
cancer recurrence were calculated using 95% conﬁdence
intervals. Survival rate was calculated for patients with and
without cancer recurrence after OLT according to the
Kaplan-Meier method, groups were compared using the log
rank test. One sided P-values <. 05 were considered sign-
iﬁcant. Analysis were done using SAS statistical software
(version 8.2).
3. Results
3.1. Patients Characteristics (Table 1). A total of 30 patients
were included for analysis. There were 23 men and 7 women
(mean age: 55 years, range 35–68 years) (22 Caucasians, 4
Asians, 3 South Americans, and 1 African).
Liver cirrhosis was mostly caused by hepatitis C virus
(HCV) and/or hepatitis B virus (HBV). Other etiologies
of cirrhosis were also identiﬁed such as alcohol abuse,
nonalcoholic steatohepatitis (NASH), and combined causes
(4HCV + alcoholism,2HCV+hemochromatosis,1HCV+
HBV, 1 HBV + alcoholism, 1 hemochromatosis + alco-
holism).
Diagnosis of HCC was based on the presence of typical
lesions on 2 imaging studies (18 patients) or on 1 imaging
study with elevation of serum alpha-fetoprotein (9 patients),
and liver biopsy was done to conﬁrm the diagnosis in
3 patients.
At the time of diagnosis, the majority of patients had
either 1 (60%) or 2 (10%) suspected tumoral nodules (size:
23,8mm ± 13.7mm (mean ± SD). A total of 6 patients
(20%) exceeded Milan criteria (Table 2).
3.2. Listing. All patients analysed were listed for OLT.
Thirteen patients (43%) were listed before having TACE and
17 (57%) after. At the time of listing, 24 patients (80%) were
within Milan criteria and 6 patients (20%) were not within
those criteria. Therefore, in these 6 patients, TACE was a
downstaging attempt.
3.3. TACE. Forty-eight TACE treatments were administered
to the 30 patients (mean 1.6/patient; range 1–7). The
majority of interventions were done in Pugh class A patients
(40 interventions or 83%) before TACE. Increase in the Pugh
class from A to B was observed following 3 TACE (6%).
Complications associated with TACE were divided into
minor and major categories (Table 3). Among the 48 TACE
procedures, 20 (42%) did not suﬀer from any complications.
A total of 27 interventions (56%) resulted in complications,
whichwereessentiallyoftheminorcategory(Table3)mostly
abdominal pain and nausea. As for major complications,International Journal of Hepatology 3
Table 1: Baseline patients characteristics.
Variable n
Number of patients 30
Sex (M/F) 23/7
Median age at listing years (range) 55 (35–68)
Origin (%)
Caucasian 22 (73)
Asian 4 (13)
South American 3 (10)
African 1 (3)
Cause of liver cirrhosis (%)
Hepatitis C virus 9 (33)
Hepatitis B virus 8 (27)
Combined causes 9 (30)
Alcohol abuse 2 (7)
NASH 2 (7)
Hepatocellular carcinoma (%) 30 (100)
Diagnosis (%)
2 imaging studies 18 (60)
1 imaging study + alfa-foeto proteins 9 (30)
Biopsy 3 (10)
Median AFP, ng/ml (range) 27,8 (2.6–3000)
Mean lesion size, mm (range) 23,8 (10–60mm)
Number of lesions, patients (%)
One lesion 18 (60)
Two lesions 3 (10)
Three lesions 7 (23)
Four lesions 2 (7)
Milan at diagnosis (%)
In 24 (80)
Out 6 (20)
Table 2: Characteristics of hepatocarcinoma outside Milan criteria
at diagnosis.
Patient number Number of lesions Size of lesions (mm)
# 13 3 45/30/26
# 16 2 50/22
#1 8 1 6 0
# 24 4 45/25/10/10
#2 7 1 5 5
# 31 3 35/22/10
we identiﬁed 2 ischemic cholecystitis, 1 acute liver failure,
1 thrombosis of the femoral artery, 1 splenic infarction, and
1 ischemic atrophy of the left hepatic lobe. In addition,
1 patient died from acute liver failure, sepsis, and acute renal
failure thought to be directly related to the TACE procedure.
3.4. Radiologic Follow-Up (Table 4). Radiologic follow-up
after TACE treatment showed a decrease of tumoral size of
at least 5mm in 13 patients (43%) (range: 5–34mm). In
6 patients (20%), tumoral size remained stable (±5mm)
and 5 patients (17%) had an increase of tumoral size of at
Table 3: Adverse events following transarterial chemoembolization
(TACE) (48 treatments in 30 patients).
Variable n
Number of TACE/patient (mean, range) 1.6 (1–7)
Adverse events (%)
None 20 (42)
Yes 28 (58)
Minor events, number of TACE (%) 24 (50)
Pain in right upper quadrant 18 (38)
Nausea/emesis 7 (15)
Chemical arteritis 5 (10)
Corticosteroids-related diabetes unbalances 2 (4)
Ischemic hepatitis 2 (4)
Leucocytosis 1 (2)
Fever 1 (2)
Allergic reaction 1(2)
Major events, number of TACE (%) 7 (15)
Ischemic cholecystitis 2 (4)
Transient acute hepatic failure 2 (4)
Thrombosis of superﬁcial femoral artery 1 (2)
Splenic infarction 1 (2)
Ischemic atrophy of the left hepatic lobe 1 (2)
Acute renal failure 1 (2)∗
Spontaneous bacterial peritonitis 1 (2)∗
Sepsis 1 (2)∗
Death 1 (2)∗
∗Those events occurred in the same patient.
least 5mm. New liver lesions were observed in 9 patients
(30%) after TACE. Therefore, a total of 10 patients (33%)
did not respond to TACE due to tumor progression and/or
appearance of new hepatic lesions. There were 6 patients
(20%) within Milan criteria at listing that were transplanted
before having radiologic follow-up after TACE and thus,
radiological response to TACE could not be assessed in these
patients.
3.5. Downstaging. As mentioned before, downstaging was
attempted in 6 patients that were exceeding Milan criteria
at HCC diagnosis. Analysis of their radiological response to
TACEshowedthatdownstaging couldbeobtainedin3ofthe
6 patients (50%).
3.6. Drop-Oﬀ (DO). During the time waiting for OLT, 4 out
of 30 patients (13%) were removed from the transplant list.
Three patients were excluded because of HCC progression
over transplant criteria and 1 died following his ﬁrst TACE
treatment. The mean delay between listing and DO was 109
days (range: 17–171 days). All 4 dropouts received 1 TACE
each before exclusion.
3.7. Orthotopic Liver Transplantation (OLT) (Table 5).
Twenty-six patients (87%) were transplanted with a mean
waiting time on the transplant list of 110 days (range: 42–
460 days). At transplantation, 22 patients (85%) met Milan4 International Journal of Hepatology
Table 4: Radiologic evolution after transarterial chemoemboliza-
tion (TACE).
Variable n
Tumor size (%)
Reduction >5mm 13 (43)
Stability +/−5mm 6 (20)
Progression >5mm 5 (17)
Unknown∗ 6 (20)
New lesions (%)
No 15 (50)
Yes 9 (30)
Unknown∗ 6 (20)
Overall response (%)
Regression (size reduction >5mm and no new lesions) 10 (33)
Stability (size stability +/−5mm and no new lesions) 4 (13)
Progression (size progression and/or new lesions) 10 (33)
Unknown 6 (20)
Downstaging (6 patients)
Yes 3 (50)
No 3 (50)
∗These patients did not have imaging after TACE before transplantation.
Table 5: Orthotopic liver transplantation.
Variable n
Patients with OLT/Patients listed for OLT 26/30
Mean waiting time in days (range) 110 (4–460)
Milan at transplantation (%)
In 22 (85)
Out 4
Progression beyond Milan criteria 2
Failed downstaging within Milan criteria 2
criteria but 4 patients (15%) exceeded Milan criteria; tumor
growth from within to beyond Milan criteria after being
listed was observed in 2 patients, downstaging failed in
2 others. These patients were transplanted despite being
beyond Milan criteria either because the tumor was at the
margin of the criteria or because of uncertainty about the
malignant nature of some nodules.
3.8. Pathology of Explanted Livers. The histopathologic anal-
ysis of the 26 explanted livers showed complete tumoral
necrosis in 10 cases (42%) and partial necrosis in 15 cases
(48%). The mean Edmondson score of patients with viable
cancer was 2,5/4. Microvascular invasion was observed in
3 cases and macrovascular invasion in one patient. In the
patients transplanted exceeding Milan criteria just before
OLT (4 cases), 1 had complete tumoral necrosis (a successful
downstaging attempt) and 3 patients (75%) had HCC that
remained outside Milan criteria at pathological analysis.
In the 10 livers where complete HCC necrosis was
observed, 9 were within Milan before transplantation. Seven
patientshadaregressionofthetumorfollowingTACE,2had
stable lesions, and 1 had new lesions identiﬁed.
Table 6: Characteristics of patients with and without cancer recur-
renceafterOLT(meanfollow-up56months;range:6–142months).
No cancer
recurrence
Cancer
recurrence P∗
n 21 5
Tumor response to TACE
regression/stability (%) 15 (71) 0 .051
Progression 2 (10) 4 (80)
Not evaluated 4 (19) 1 (20)
Milan criteria before OLT (%)
within Milan 19 (90) 3 (60) .1548
outside Milan 2 (10) 2 (40)
Pathological tumor analysis (%)
complete necrosis 10 (48) 0 .066
microscopic invasion 0 3 (60) .004
Mortality 2 (10) 4 (80) .002
∗One sided P-values calculated using the Fisher exact test.
3.9. Follow-Up. Table 6 summarizes patients’ characteristics
after OLT with a mean follow-up of 56 months (range: 6–
142 months). At follow-up, we identiﬁed 21 patients (81%)
without cancer recurrence and 5 with cancer recurrence
(19%).Inpatientsidentiﬁedwithcancerrecurrence,3(60%)
had cancer in the transplanted liver and 2 (40%) had lung
metastasis. Mean time to recurrence was 13.8 months (range
6–22 months).
Patients without cancer recurrence had more tumoral
regression/stability after TACE than patients with cancer
recurrence (71% versus 0%; P = .051). In addition, patients
with no tumoral recurrence were almost all within Milan
criteria before transplantation (90%) as opposed to patients
with tumoral recurrence (60%). Therefore, Milan status was
associated to a relative risk of cancer recurrence posttrans-
plantation of 6.33 with a 95% CI (1.53–26.18). Patients with
no cancer recurrence showed more complete necrosis (48%
versus 0%; P = .066) and signiﬁcantly less microscopic inva-
sion (0% versus 60%; P = .004) on pathological analysis.
Six patients died (23%) at follow-up: 1 from postoper-
ative complications, 4 from cancer recurrence, and 1 from
cirrhosis associated with hepatitis C 7 years posttransplanta-
tion (Figure 1). Therefore, survival of patients with tumor
recurrence was poor, mortality was signiﬁcantly lower in
patients without cancer recurrence compared to patients
with cancer recurrence (10% versus 80%; P = .002).
3.10. Subgroup Analysis according to Milan Status. In the 4
patients that exceeded Milan criteria before transplantation,
2 represented a failed attempt at downstaging and cancer
progression was observed in 2. Three of the 4 patients (75%)
exceeding Milan at OLT had HCC discovered at histology.
At follow-up, HCC recurrence was observed in 2 of these
patients (50%). Hence, being outside Milan before OLT
signiﬁcantly increased risk of cancer recurrence after OLT
(RR: 6.33, 95% CI: 1.53–26.18).
In the 22 patients within Milan criteria before trans-
plantation, 10 (45%) had complete HCC necrosis and allInternational Journal of Hepatology 5
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Figure 1: Cumulative proportion of patients surviving after OLT
(Kaplan-Meier plot) with and without cancer recurrence. The
diﬀerence between the 2 groups was signiﬁcant (P<. 01; log rank
test).
remaining HCC were within Milan criteria at pathology.
So far, 3 patients (14%) had HCC recurrence after OLT.
Five died (23%), 1 from postoperative complications, 3
fromHCCrecurrence,and1fromcirrhosis7yearsafterOLT.
4. Discussion
Hepatocellular carcinoma represents a serious disease with
a high mortality rate. When a tumor is centrally located
within an underlying cirrhosis, the best treatment is liver
transplantation. However, tumoral size is a major determi-
nantofeligibilityfortransplantation.Moreover,timewaiting
for an organ is associated with tumoral growth, which
is responsible for most dropouts. Over the years, several
approaches including TACE were used to limit tumoral
growth in cirrhotic patients on the waiting list and hopefully
tumor recurrence after transplantation. Some researchers
stated that the response to TACE could be used to predict
risks of tumor recurrence after liver transplantation [15–18].
However, these studies are diﬃcult to analyse as they are
either using diﬀerent chemotherapeutic agents or do not
include a pathological analysis of explanted livers.
Milan criteria are used in most transplant centers to
select patients eligible for liver transplantation. Extended
criteriaareuncommonlyusedinsomecenters,withthemost
recognized being the San Francisco criteria. It has also been
suggested that TACE can be used to downstage the tumor
within Milan criteria or within San Francisco criteria before
transplantation [19–24].
The present study reports our experience with cirrhotic
patients with HCC who underwent TACE and who were
listed for OLT between January 1996 and January 2008. Only
patients within Milan criteria were eligible for transplanta-
tion. We analysedretrospectively tumoralresponse following
TACE treatments, incidence of dropouts on the waiting list,
histopathological characteristics of HCC on explanted livers,
and evolution of patients after transplantation. Although a
small number of patients were analyzed, interesting ﬁndings
were observed.
We conﬁrm that TACE can inﬂuence tumoral growth
in most patients while waiting for transplantation. Forty-
eight TACE in 30 patients were performed: a decrease of
tumoral size was observed in 13 patients and an increase
in 5 patients. Twelve patients had stable lesions. Therefore,
among 30 transplant candidates, 26 could be operated,
with 4 being dropped out (3 due to tumor progression).
Histopathological analysis of the 26 explanted liver showed
complete necrosis of HCC in 10, reinforcing the eﬀectiveness
of TACE treatments. Subgroup analysis of these patients
with no residual carcinoma showed that 9 patients (90%)
were within Milan before OLT and that none had cancer
progression observed after TACE treatments.
Despite our intent to transplant only patients within
the Milan criteria, 4 patients exceeding these criteria were
operated. This emphasizes the diﬃculty to evaluate correctly
the tumoral stage using radiologic imaging. In these four
patients, the disease was thought to be at the margin of
Milan criteria or the exact nature of some nodules was falsely
presumedto bebenign. This diﬃculty of correctlyevaluating
tumoral size and extension is observed in most transplant
centers.
As previously stated, TACE could be used either to
limit tumoral growth within Milan criteria or to downstage
HCC. In 6 patients, downstaging was attempted using TACE
before transplantation and this was successful for 3 patients
(50%). In these patients, the pathological analysis either
demonstrated variable level of HCC necrosis (2 patients)
or complete necrosis of HCC (1 patient). Follow-up after
transplantation showed that none of these 3 patients had
tumor recurrence or died. Such eﬀective downstaging within
the transplant criteria using TACE without increasing the
risk of cancer recurrence has also been reported by other
research teams [19–24].
Our results support the use of Milan criteria to select
patients for liver transplantation. Patients within Milan
t r e a t e dw i t hO L Th a dh i g hl e v e l so fn e c r o s i so nh i s t o p a t h o -
logical analysis (45% did not have residual HCC), very low
rateofHCCrecurrence(14%),andlowmortalityrateduring
follow-up (23%), which is in accordance with the literature
[19, 20, 23, 24]. Patients exceeding Milan before transplan-
tation had little necrosis on histopathological analysis (75%
had viable HCC), high rate of cancer recurrence, and death
within 2 years of surgery.
As shown by others [15–18], the response to TACE
provides important information for the prognosis after
transplantation. A signiﬁcant number of patients who did
not respond to TACE, even if the tumor was still within
the Milan criteria, demonstrated postoperative tumoral
recurrence. This is best explained by the aggressiveness of
the tumor. Therefore, response to TACE could be used as
an additional tool in order to better select patients for
transplantation [25].
The tolerance to TACE was rather good as previously
reported [13] but several major complications occurred after6 International Journal of Hepatology
TACE including acute transient hepatic insuﬃciency, 1 is-
chemic cholecystitis, femoral artery thrombosis, and splenic
infarction; only one patient died from sepsis and acute
hepato-renal failure.
These encouraging results must be tempered by the fact
thatourpopulationwassmallandhighlyselectedandalsoby
the possible adverse events following TACE. TACE was only
performed in patients with good liver function, patent portal
vein, and absence of signiﬁcant portosystemic shunting.
Therefore,ourconclusionscannotbeextrapolated toalarger
population.
5. Conclusion
In conclusion, the present study conﬁrms the usefulness
of TACE as a bridge to liver transplantation in cirrhotic
patients with hepatocellular carcinoma within the Milan
criteria and also to downstage some highly selected patients.
This approach is associated with a good survival rate and a
low rate of cancer recurrence. TACE was also well tolerated.
These encouraging results could be improved in the future
by a better selection of transplant candidates based on
more accurate imaging techniques and better assessment of
biological characteristics of HCC.
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